Atrial Fibrillation in COVID-19: From Epidemiological Association to Pharmacological Implications

Area of Science:

• Cardiology
• Infectious Diseases
• Pharmacology

Background:

• The COVID-19 pandemic, caused by SARS-CoV-2, presents unique challenges for patients with cardiovascular diseases.
• Atrial fibrillation is a common arrhythmia, and its management may be complicated by COVID-19 infection and its treatments.

Purpose of the Study:

• To review potential pharmacological interactions between commonly used atrial fibrillation drugs and experimental COVID-19 therapies.
• To provide guidance on optimal management strategies for patients with atrial fibrillation during the COVID-19 pandemic.

Main Methods:

• Systematic review of the literature.
• Analysis of drug interaction data based on EU and US summaries of product characteristics.
• Focus on cardiovascular drugs for atrial fibrillation and emerging COVID-19 treatments.

Main Results:

• Identified potential interactions between specific antiarrhythmic drugs and antiviral or immunomodulatory COVID-19 therapies.
• Highlighted the need for careful monitoring of patients receiving combined treatments.
• Emphasized the importance of consulting drug interaction databases and product information.

Conclusions:

• Pharmacological interactions between atrial fibrillation medications and COVID-19 therapies require careful consideration.
• Individualized patient management is essential to minimize risks and optimize outcomes.
• Further research is needed to fully elucidate the safety and efficacy of combined treatment regimens.